Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
University of Texas Southwestern Medical Center National Heart, Lung, and Blood Institute (NHLBI) |
---|---|
Information provided by: | University of Texas Southwestern Medical Center |
ClinicalTrials.gov Identifier: | NCT00827775 |
Condition | Intervention | Phase |
---|---|---|
Intradialytic Hypertension |
Drug: Carvedilol |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment |
Official Title: | Blood Pressure, Endothelial Cell Dysfunction, and Outcomes in Dialysis Patients |
Estimated Enrollment: | 50 |
Study Start Date: | March 2009 |
Estimated Study Completion Date: | June 2011 |
Estimated Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Control: No Intervention
Patients without intradialytic hypertension defined as average pre to post hemodialysis SBP falling >10 mmhg for more than 4/6 of the last dialysis treatment sessions
|
|
Intervention: Active Comparator
Patients with intradialytic hypertension defined as average pre to post hemodialysis SBP elevation of >10 mmhg for more than 4/6 of the last dialysis treatment sessions
|
Drug: Carvedilol
Carvedilol 6.25 mg BID titrated weekly to maximun of 25 mg bid
|
Ages Eligible for Study: | 18 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Jula K Inrig, MD, MHS | 214-645-8263 | jula.inrig@utsouthwestern.edu |
Contact: Tammy Lightfoot, RN | 214-645-8265 | tammy.lightfoot@utsouthwestern.edu |
Principal Investigator: | Jula K Inrig, MD, MHS | UT Southwestern Medical Center |
Responsible Party: | UT Southwestern ( Jula K Inrig, MD, MHS ) |
Study ID Numbers: | 102008-042, NIH K23 HL092297 |
Study First Received: | January 21, 2009 |
Last Updated: | January 22, 2009 |
ClinicalTrials.gov Identifier: | NCT00827775 History of Changes |
Health Authority: | United States: Institutional Review Board |
Hypertension Hemodialysis |
Vasodilator Agents Neurotransmitter Agents Adrenergic Agents Vascular Diseases Adrenergic beta-Antagonists Adrenergic Antagonists |
Adrenergic alpha-Antagonists Cardiovascular Agents Antihypertensive Agents Carvedilol Hypertension |
Vasodilator Agents Neurotransmitter Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Vascular Diseases Adrenergic alpha-Antagonists Cardiovascular Agents |
Antihypertensive Agents Pharmacologic Actions Therapeutic Uses Adrenergic beta-Antagonists Cardiovascular Diseases Adrenergic Antagonists Hypertension Carvedilol |